<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Causes and diagnosis of AA amyloidosis and relation to rheumatic diseases
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Causes and diagnosis of AA amyloidosis and relation to rheumatic diseases
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Causes and diagnosis of AA amyloidosis and relation to rheumatic diseases
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter D Gorevic, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen J Lachmann, MA, MB, BChir, MD, FRCP, FRCPath, FMedSci
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Siobhan M Case, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA amyloidosis (previously known as secondary [AA] amyloidosis) is a disorder characterized by the extracellular tissue deposition of fibrils that are composed of fragments of and/or intact serum amyloid A protein (SAA), a hepatic acute phase reactant. (See
         <a class="medical medical_review" href="/z/d/html/5619.html" rel="external">
          "Pathogenesis of AA amyloidosis"
         </a>
         .)
        </p>
        <p>
         AA amyloidosis may complicate any chronic inflammatory condition, including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), inflammatory bowel disease, familial periodic fever syndromes, chronic infections, and certain neoplasms (
         <a class="graphic graphic_table graphicRef112212" href="/z/d/graphic/112212.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The major causes and approach to diagnosis of AA amyloidosis are presented here. The clinical manifestations and treatment of AA amyloidosis and the musculoskeletal and renal manifestations of amyloid diseases are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5588.html" rel="external">
          "Treatment of AA (secondary) amyloidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5616.html" rel="external">
          "Musculoskeletal manifestations of amyloidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3120.html" rel="external">
          "Renal amyloidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CAUSES AND RELATION TO RHEUMATIC DISEASES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple chronic inflammatory conditions, among them rheumatologic, autoinflammatory, chronic infectious, and other disorders, have been associated with the development of AA amyloid [
         <a href="#rid1">
          1,2
         </a>
         ]. The most common organ system involved in this form of amyloidosis is the kidney, although other organ systems are often also affected. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2559122869">
         <span class="h2">
          Epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The disorders most often identified as underlying AA amyloidosis have varied over time and geographically, reflecting the prevalent chronic inflammatory conditions. During the 20
         <sup>
          th
         </sup>
         century, AA amyloidosis has become less common and the contribution of AA amyloid to large series of amyloidosis has gradually decreased. The underlying causes of chronic inflammation have also changed; inflammatory arthritides have become the most common underlying disease, replacing chronic infections, particularly tuberculosis [
         <a href="#rid3">
          3
         </a>
         ] and osteomyelitis, which had historically been the predominant causes. With widespread availability of highly effective antimicrobial agents, the infectious causes have become less common in much of the world [
         <a href="#rid4">
          4
         </a>
         ], and it is anticipated that therapeutic advances in the treatment of rheumatologic and other inflammatory disorders with highly effective biologic agents will result in fewer patients developing amyloidosis [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Both the annual incidence and population prevalence of AA amyloidosis appear to be decreasing in national surveys from some western countries, presumably reflecting advances in therapeutics of the underlying disorders [
         <a href="#rid6">
          6-8
         </a>
         ]. The overall autopsy incidence of AA amyloidosis in western nations ranges from 0.5 to 0.86 percent [
         <a href="#rid9">
          9,10
         </a>
         ]. In the United Kingdom, the estimated incidence of AA amyloidosis was 0.166 per 100,000 in 2008 [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The list of chronic inflammatory conditions reported in association with AA amyloidosis is extensive, including chronic inflammatory arthritides, vasculitides, inflammatory bowel disease, periodic fever syndromes, chronic infections, neoplasms, and other disorders (
         <a class="graphic graphic_table graphicRef112212" href="/z/d/graphic/112212.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The following frequencies of underlying disorders have been found in large series of patients with AA amyloidosis from two large centers in the United States [
         <a href="#rid9">
          9,11,12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Idiopathic – 21 to 29 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rheumatoid arthritis (RA) or juvenile idiopathic arthritis (JIA) – 12 to 21 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inflammatory bowel disease – 16 to 17 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spondyloarthritis/psoriasis – 10 to 12 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Familial Mediterranean fever – 4 to 5 percent
        </p>
        <p>
        </p>
        <p>
         Two series of patients with AA amyloidosis in the United Kingdom, the larger of which included 374 subjects, found the following associated diseases [
         <a href="#rid13">
          13-15
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adult RA – 23 to 51 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         JIA – 11 to 17 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic infection – 9 to 15 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hereditary periodic fever syndromes (eg, familial Mediterranean fever) – 9 to 11 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ankylosing spondylitis (AS) – 0 to 12 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psoriatic arthritis – 4 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Crohn disease – 2 to 5 percent
        </p>
        <p>
        </p>
        <p>
         In some other parts of the world, hereditary periodic fevers and infections are responsible for a larger proportion of cases of AA amyloid [
         <a href="#rid16">
          16
         </a>
         ]. As an example, in Turkey, familial Mediterranean fever is the cause of more than 60 percent of cases [
         <a href="#rid17">
          17
         </a>
         ]. In Armenia, and among Armenian populations in surrounding countries, familial Mediterranean fever is common, and the carrier rate for
         <em>
          MEFV
         </em>
         gene mutations approaches one in five individuals. Further genetic work in this population has shown that
         <em>
          MEFV
         </em>
         M694V (the commonest mutation underlying familial Mediterranean fever) is associated with a greater risk of developing AA amyloidosis. A further genetic contribution to the risk of AA amyloidosis is homozygosity for the SAA1.1 allele, and patients who are homozygous for both
         <em>
          MEFV
         </em>
         M694V and SAA1.1 have a sevenfold increased risk of developing renal amyloidosis, compared with other
         <em>
          SAA1
         </em>
         genotypes [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
         Other conditions that may be associated with AA amyloid include neoplasms, particularly renal cell carcinoma [
         <a href="#rid20">
          20
         </a>
         ], non-Hodgkin lymphoma [
         <a href="#rid21">
          21
         </a>
         ], Waldenström macroglobulinemia [
         <a href="#rid22">
          22
         </a>
         ] and other gammopathies [
         <a href="#rid23">
          23
         </a>
         ], Castleman disease [
         <a href="#rid24">
          24-26
         </a>
         ], and non-neoplastic conditions such as cystic fibrosis [
         <a href="#rid27">
          27,28
         </a>
         ], abuse of injected drugs [
         <a href="#rid29">
          29
         </a>
         ], and hidradenitis suppurativa [
         <a href="#rid30">
          30,31
         </a>
         ]. In the United Kingdom experience, the contribution of AA amyloidosis due to chronic infection due to recreational drug use rose from 1 percent in 1990 to 1997 to 13 percent in 2007 to 2014 [
         <a href="#rid8">
          8
         </a>
         ], an experience mirrored in a series of intravenous drug users in San Francisco [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         A striking change since 1990 has been the increasing proportion of patients with underlying inflammation of unknown etiology even after extensive investigation by experienced centers. In a study of the changes in causation over 25 years, AA amyloidosis of unknown etiology rose from 10 to 27 percent of new cases [
         <a href="#rid8">
          8
         </a>
         ]. Some of this might be explained by the obesity epidemic, as this has been identified as an emerging cause of AA amyloid, with resultant renal disease, in association with findings suggesting low-grade but chronic inflammation probably due to cytokine production by adipocytes [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p>
         Geographic variation may result from additional factors beyond causative or associated disease prevalence and the availability of effective therapies. Studies of the prevalence of AA amyloidosis complicating juvenile arthritis from the 1960s and 1970s reported an almost 100-fold variation between the United States and Poland [
         <a href="#rid34">
          34-36
         </a>
         ]. As a subsequent example, in familial Mediterranean fever, the development of AA amyloidosis is related to severity and duration of disease and homozygosity for the M694V variant, but in a large study, geography was identified as the leading risk factor [
         <a href="#rid37">
          37
         </a>
         ]. Whether the country of origin reflects genetic factors associated with ethnicity or environmental factors is not yet clear. (See
         <a class="medical medical_review" href="/z/d/html/2635.html" rel="external">
          "Clinical manifestations and diagnosis of familial Mediterranean fever"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Rheumatoid arthritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Susceptibility to AA amyloidosis in RA is related to duration of the disease activity, greater disability, and higher levels of inflammation. Amyloidosis is more likely to occur in patients with poorly controlled, seropositive, severe, and longstanding disease occurring in association with other extraarticular manifestations. Renal, gastrointestinal, and cardiac manifestations of amyloidosis are most common, but in the majority of patients, the disease remains subclinical.
        </p>
        <p>
         The reported postmortem incidence of amyloid complicating adult RA has generally ranged from 10 to 25 percent, although studies of patients from the 1930s and 1940s reported 60 percent involvement [
         <a href="#rid38">
          38
         </a>
         ]. Similar values of 7.1 to 29 percent have been found with subcutaneous fat pad aspirates or gastrointestinal biopsies in living patients with RA in studies published between 1993 and 2004 [
         <a href="#rid39">
          39-44
         </a>
         ]. In these studies, AA amyloid was clinically overt in only 25 to 50 percent, even after long periods of follow-up sampling, indicating the majority of cases were subclinical [
         <a href="#rid40">
          40,42
         </a>
         ].
        </p>
        <p>
         Symptomatic disease diagnosed pre-mortem has been reported in 2 to 11 percent, with considerable variation among geographic areas [
         <a href="#rid38">
          38,42
         </a>
         ]. In a 1999 population-based series of 1666 subjects with RA who had died in Finland, the prevalence of amyloidosis was 5.8 percent [
         <a href="#rid45">
          45
         </a>
         ]. The yield of amyloid among patients with RA and renal disease ranges from 10 to 30 percent [
         <a href="#rid46">
          46-48
         </a>
         ].
        </p>
        <p>
         The clinical spectrum of amyloidosis in RA was evaluated in a report of 124 patients from Japan [
         <a href="#rid41">
          41
         </a>
         ]. The following observations were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Major manifestations and their frequency included:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nephropathy – 59 percent (see
         <a class="medical medical_review" href="/z/d/html/3120.html" rel="external">
          "Renal amyloidosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gastrointestinal symptoms – 58 percent (see
         <a class="medical medical_review" href="/z/d/html/2642.html" rel="external">
          "Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cardiomyopathy – 40 percent (see
         <a class="medical medical_review" href="/z/d/html/122846.html" rel="external">
          "Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The mean duration of RA at diagnosis of amyloidosis was 15.4 years
        </p>
        <p>
        </p>
        <p>
         Similar findings were noted in a retrospective review of 91 Dutch patients with AA amyloidosis due to RA [
         <a href="#rid49">
          49
         </a>
         ]. Nephropathy was the most common presenting symptom, being manifested as proteinuria (70 percent) or impaired renal function. Other organ systems were less frequently involved: cardiomyopathy (9 percent), gastrointestinal symptoms (24 percent), and hepatomegaly (19 percent).
        </p>
        <p>
         The development of amyloidosis has traditionally been associated with a relatively poor prognosis, unless the underlying RA can be effectively treated. It has been estimated to be the cause of death of 2 to 8 percent of adult patients coming to autopsy [
         <a href="#rid38">
          38
         </a>
         ]. A 1994 report from Japan found a four-year survival rate of 58 percent from the time of diagnosis of amyloidosis, with renal failure contributing to 39 percent of deaths [
         <a href="#rid41">
          41
         </a>
         ]; a subsequent series over a decade later reported an improvement to 67 months in the mean survival following the diagnosis of AA amyloidosis [
         <a href="#rid50">
          50
         </a>
         ]. Prognosis may be significantly impacted by whether amyloid deposition is glomerular or purely vascular in RA patients with AA deposition [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Similarly, a study from Finland found that the diagnosis of amyloidosis shortened the lifespan of RA patients by 7.7 years [
         <a href="#rid45">
          45
         </a>
         ]; a reevaluation of autopsy material for the period from 1952 to 1991 from Finland reported a 30 percent incidence of AA amyloid compared with 18 percent detected on routine testing, indicating that a significant proportion of patients may not have been appreciated by standard histologic analysis [
         <a href="#rid52">
          52,53
         </a>
         ]. In contrast with the time period sampled above, subsequent (1987 to 1997) surveys from Finland appeared to confirm a decreasing incidence of AA amyloid among RA patients, possibly reflecting the impact of newer drugs and treatment regimens and of more aggressive treatment standards for early disease [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Juvenile idiopathic arthritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In early reviews, juvenile chronic polyarthritis, also known as juvenile idiopathic arthritis (JIA), accounted for 43 percent of cases of amyloidosis occurring under age 18, with a 4 to 6 percent incidence reported among 389 cases of systemic JIA (Still's disease) followed over a 10-year period [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Renal involvement, manifested clinically as proteinuria, occurs in almost all affected patients. Symptomatic disease is also relatively common. One report, for example, found the following frequency of symptoms [
         <a href="#rid54">
          54
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Edema – 53 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension – 25 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         End-stage kidney disease – 2.5 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe abdominal pain, hepatomegaly, and splenomegaly – approximately 20 percent each
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diarrhea – 13 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ascites – 2.5 percent
        </p>
        <p>
        </p>
        <p>
         Amyloidosis had been estimated to be the cause of death of 43 to 47 percent of European patients with JIA in the mid-20
         <sup>
          th
         </sup>
         century, but the introduction of more effective treatments that lessen the chronic inflammation associated with systemic JIA has been associated with a dramatic reduction in the incidence of JIA-associated AA amyloidosis. Serial retrospective reviews from the United Kingdom's National Amyloidosis Centre showed a drop in JIA as an association for AA amyloid from 25 percent for the period 1990 to 1997 to 2 percent for 2007 to 2014 [
         <a href="#rid8">
          8
         </a>
         ]; similarly, no cases have been documented in the Finnish registry since 1991 [
         <a href="#rid38">
          38,55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6400.html" rel="external">
          "Systemic juvenile idiopathic arthritis: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Ankylosing spondylitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         AS, a form of axial spondyloarthritis, is a well-established cause of AA amyloidosis, and AA amyloidosis was more common among AS patients than RA patients in a multicenter study from Turkey [
         <a href="#rid56">
          56
         </a>
         ]. Renal involvement is the primary clinical manifestation.
        </p>
        <p>
         The Medical Research Council studies, performed in Britain in the 1950s, found a 6 percent incidence of amyloidosis in patients dying with AS; the diagnosis was made pre-mortem in only 11 of 25 affected patients [
         <a href="#rid57">
          57
         </a>
         ]. A 7 to 9 percent incidence has been reported in a series in which random rectal or fat pad biopsies were performed [
         <a href="#rid58">
          58,59
         </a>
         ]. Subsequently, a 4.3 percent incidence was reported, primarily in patients with severe chronic disease [
         <a href="#rid59">
          59,60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Systemic lupus erythematosus
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA amyloidosis has been described in only a small number of patients with systemic lupus erythematosus (SLE) [
         <a href="#rid61">
          61
         </a>
         ]. The reason for the lower incidence of amyloidosis in SLE relative to RA is unknown but may be due to characteristically lower serum amyloid A protein (SAA) levels [
         <a href="#rid62">
          62
         </a>
         ]. An increased predilection for circulating SAA to undergo proteolytic cleavage in RA compared with SLE has also been proposed [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Other rheumatic diseases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Scattered case reports have noted AA amyloidosis in a number of other rheumatic diseases. These include reactive arthritis (formerly Reiter syndrome) [
         <a href="#rid64">
          64
         </a>
         ], psoriatic arthritis [
         <a href="#rid65">
          65
         </a>
         ], Behçet syndrome [
         <a href="#rid66">
          66
         </a>
         ], Takayasu arteritis [
         <a href="#rid67">
          67,68
         </a>
         ], Whipple's disease [
         <a href="#rid69">
          69
         </a>
         ], polymyalgia rheumatica [
         <a href="#rid70">
          70
         </a>
         ], giant cell (temporal) arteritis [
         <a href="#rid71">
          71
         </a>
         ], polyarteritis nodosa [
         <a href="#rid72">
          72
         </a>
         ], gout [
         <a href="#rid73">
          73
         </a>
         ], Sjögren's disease [
         <a href="#rid74">
          74
         </a>
         ], and immunoglobulin (Ig)G4-related disease [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          'Hereditary' AA amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA amyloidosis is not directly inherited, but there is evidence for genetic predisposition; in children with familial Mediterranean fever, multivariate analysis has shown that the presence of a family history of amyloidosis plus consanguinity was associated with a sixfold increased risk of developing AA amyloidosis [
         <a href="#rid76">
          76
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">
          "The autoinflammatory diseases: An overview"
         </a>
         ). In one well-described family, AA amyloid occurred over multiple generations linked to a variant in the
         <em>
          SAA1
         </em>
         promoter [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1552655698">
         <span class="h2">
          AA amyloidosis in the spectrum of autoinflammatory diseases
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA amyloidosis may complicate autoinflammatory diseases characterized by monogenic inheritance.
        </p>
        <p>
         These include familial Mediterranean fever and other periodic fever syndromes, which may also have rheumatic symptoms, and are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Familial Mediterranean fever (see
         <a class="medical medical_review" href="/z/d/html/2635.html" rel="external">
          "Clinical manifestations and diagnosis of familial Mediterranean fever"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cryopyrin-associated periodic syndromes (see
         <a class="medical medical_review" href="/z/d/html/5585.html" rel="external">
          "Cryopyrin-associated periodic syndromes and related disorders"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor necrosis factor receptor-1 (TNFR1) associated periodic syndrome (see
         <a class="medical medical_review" href="/z/d/html/5580.html" rel="external">
          "Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mevalonate kinase deficiency (see
         <a class="medical medical_review" href="/z/d/html/5954.html" rel="external">
          "Hyperimmunoglobulin D syndrome: Clinical manifestations and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         In these syndromes, AA amyloidosis may precede the characteristic clinical phenotype [
         <a href="#rid78">
          78,79
         </a>
         ], which for familial Mediterranean fever has been designated "phenotype 2." Overlap between inflammation, IgM kappa gammopathy, and the occasional development of AA amyloid may also be found in Schnitzler syndrome, characterized by recurrent episodes of urticarial rash [
         <a href="#rid80">
          80
         </a>
         ]. Lastly, AA amyloid may complicate sporadic autoinflammatory diseases that include JIA [
         <a href="#rid81">
          81
         </a>
         ], adult-onset Still's disease [
         <a href="#rid82">
          82
         </a>
         ], gout [
         <a href="#rid73">
          73
         </a>
         ], and there has been one case report of AA amyloidosis in the newly described disease VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic), which is due to an acquired somatic mutation in
         <em>
          UBA1
         </em>
         [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Idiopathic AA amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In small but increasing numbers, the underlying cause of the chronic inflammatory state remains obscure, despite an extensive evaluation for underlying inflammatory or infectious causes [
         <a href="#rid14">
          14
         </a>
         ]. In three well-characterized single-center series of patients with AA amyloidosis from the United States, approximately 20 percent of cases were found to be idiopathic at diagnosis, with a small percentage revealing a known association later in the course [
         <a href="#rid11">
          11,12,84
         </a>
         ]. In two subsequent large series of patients with AA amyloid seen at referral centers in the United Kingdom and Italy, the underlying disease remained unknown in 19 and 32 percent, respectively [
         <a href="#rid8">
          8,85
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1491288993">
         <span class="h2">
          Changing face of disease and survival
         </span>
         <span class="headingEndMark">
          —
         </span>
         The observation that AA amyloidosis is becoming less common [
         <a href="#rid8">
          8
         </a>
         ] may be a reflection of advances in treatment of inflammatory arthritis in the era of biologic agents. This has both reduced the incidence of AA amyloidosis, and, when it does develop, has improved outcomes in what were previously the commonest pathologies underlying AA amyloidosis. In addition, the older age of the United Kingdom cohort (62 years in 2007 to 2014 versus 54 years in 1990 to 1997) may well reflect both the impact of better treatments, such as biologics, and more willingness to aggressively investigate and manage older patients. In the latest cohort, there was a significantly increased proportion of patients in end-stage kidney disease (29 versus 15 percent) compared with the earliest – a both unexpected and disappointing observation. Possible explanations include age-related decreased renal reserve resulting in more rapid loss of renal function in the presence of AA amyloidosis. While overall survival does not appear to have changed despite new effective therapies, age at death has increased significantly over the last 25 years, suggesting improved general management and supportive care, including renal transplantation [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The median survival among cohorts of patients with AA amyloidosis has improved from 24.5 months in a series of 64 in 1991 from the United States [
         <a href="#rid86">
          86
         </a>
         ] to 140 months in 375 patients from the United Kingdom in 2007 [
         <a href="#rid14">
          14
         </a>
         ] and 143 months for 200 patients in Italy in 2017 [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA amyloidosis can affect a variety of organs, including the kidneys and heart. These and other manifestations are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         The most common organ system involved in AA amyloid is the kidney (approximately 90 percent). This is usually characterized by glomerular amyloid deposition, typically leading to the nephrotic syndrome (
         <a class="graphic graphic_picture graphicRef63840 graphicRef78183 graphicRef54148 graphicRef75254" href="/z/d/graphic/63840.html" rel="external">
          picture 1A-D
         </a>
         ) [
         <a href="#rid8">
          8,11-15
         </a>
         ]. However, variant forms occur in which the deposits are predominantly vascular [
         <a href="#rid87">
          87
         </a>
         ] or tubular [
         <a href="#rid88">
          88
         </a>
         ], with some evidence indicating that the AA protein in these forms is biochemically distinct (
         <a class="graphic graphic_picture graphicRef80029 graphicRef63533" href="/z/d/graphic/80029.html" rel="external">
          picture 2A-B
         </a>
         ) [
         <a href="#rid87">
          87-89
         </a>
         ]. Patients with these variant forms of renal amyloid may present with progressive renal failure, a relatively bland urinary sediment, and little proteinuria, or they may show signs of primary tubular dysfunction such as arginine vasopressin resistance (AVP-R, previously called nephrogenic diabetes insipidus) [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3120.html" rel="external">
          "Renal amyloidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tissue biopsy is necessary to confirm the presence of amyloid, although the diagnosis of AA amyloidosis may be suggested by clinical features and by the presence of a predisposing rheumatic or a chronic inflammatory disease (eg, nephrotic syndrome occurring in the setting of longstanding rheumatoid arthritis [RA]), and additional laboratory testing may be needed to exclude other conditions. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Diagnosis'
         </a>
         and
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3407316663">
         <span class="h2">
          Diagnostic approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         We take the following approach to diagnosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In all patients with suspected AA amyloidosis, we recommend tissue biopsy to confirm the presence of amyloid. The abdominal fat is a generally safe and reasonably sensitive site for initial biopsy. In patients with a negative fat aspiration biopsy, we perform a biopsy of a clinically involved organ. (See
         <a class="local">
          'Biopsy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Selection of biopsy site'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternatives to abdominal fat biopsies for screening include rectal and gingival biopsies. Amyloidosis is very unlikely in a patient with a negative screening biopsy and a negative biopsy of adequate tissue from an affected organ by a laboratory with expertise in these techniques.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Scintigraphy with radioisotope labeled serum amyloid P component (SAP) is also a useful screening technique for suspected amyloidosis, but its availability has been limited to the United Kingdom and the Netherlands, and it is not available in the United States. (See
         <a class="local">
          'Serum amyloid P component scintigraphy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients in whom amyloid is present on biopsy, further immunofluorescence or immunohistochemical staining for AA protein and for kappa and lambda light chains is indicated to confirm the diagnosis of AA amyloidosis and to exclude immunoglobulin light chain (AL; primary) amyloidosis. (See
         <a class="local">
          'Biopsy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Positive immunohistochemical staining of amyloid deposits with monospecific anti-AA protein antiserum is highly specific for AA amyloidosis when performed in expert centers. For confirmation of the diagnosis, to exclude AL amyloidosis, and if immunohistochemistry is equivocal or unavailable, we test serum and urine for monoclonal immunoglobulins by performing serum immunofixation and test serum for free light chains. (See
         <a class="local">
          'Laboratory testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Biopsy of the subcutaneous fat, rectal or gingival tissue, or a clinically involved organ is used to document the presence of amyloid. These individual techniques are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Selection of biopsy site'
         </a>
         .)
        </p>
        <p>
         The fat pad biopsy can establish the diagnosis in up to 80 percent of cases and can be combined with immunoelectron microscopy and mass spectroscopy.
        </p>
        <p>
         Numerous studies support the use of a biopsy of the rectal mucosa and submucosa, with a sensitivity of approximately 75 to 85 percent for the detection of amyloid deposits. However, some series have shown lower sensitivity than abdominal fat aspiration. Considering that the involvement of the gastrointestinal tract may be focal, vascular, and subtle, sampling of multiple locations in the gastrointestinal tract (eg, stomach, small bowel, or colon) may also be useful for diagnosis [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         Immunofluorescence (as well as immunohistochemical and immunoelectron) microscopy with a monospecific anti-AA protein antiserum is typically markedly positive in AA amyloidosis (
         <a class="graphic graphic_picture graphicRef75254" href="/z/d/graphic/75254.html" rel="external">
          picture 1D
         </a>
         ) [
         <a href="#rid91">
          91,92
         </a>
         ] (see
         <a class="local">
          'Diagnosis'
         </a>
         above). Absence of staining for lambda or kappa light chains further helps to distinguish AA from AL amyloidosis. These analyses should be performed by centers with expertise in these techniques.
        </p>
        <p>
         For further analysis, amino acid sequencing and mass spectroscopy of amyloid deposits have been utilized to identify the precursor protein [
         <a href="#rid93">
          93-95
         </a>
         ] and are available commercially [
         <a href="#rid96">
          96
         </a>
         ]. Quantitation of AA amyloid in abdominal fat pad aspirates has been demonstrated using an enzyme-linked immunosorbent assay (ELISA); this approach may have utility for comparing patient population and for monitoring AA deposition serially [
         <a href="#rid94">
          94
         </a>
         ]. A full proteomics approach combined with immunoelectron microscopy of fat pad aspirates establishes the diagnosis of AA amyloidosis in 70 to 80 percent of cases [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         We obtain a serum C-reactive protein (CRP) level and an erythrocyte sedimentation rate (ESR) to assess the acute phase response for evidence of an inflammatory state. These are sometimes useful for monitoring of therapy [
         <a href="#rid12">
          12
         </a>
         ]. However, other than the biopsy-related studies (see
         <a class="local">
          'Biopsy'
         </a>
         above), laboratory testing has little role in confirming the presence of AA amyloidosis. An important limitation regarding the ESR as a measure of inflammation in some patients with amyloidosis is the elevation seen in this assay in patients with chronic kidney disease and proteinuria, even in the absence of inflammation.
        </p>
        <p>
         Demonstration of a sustained inflammation with a raised CRP, ESR (except in patients with chronic kidney disease, in whom the test may be elevated without inflammation), or other hepatic acute phase response testing is suggestive of chronic inflammation that might result in AA amyloidosis. We typically perform such testing every two to four weeks over at least a two-month period to assess inflammatory activity. It would be very unusual to have AA amyloidosis with a normal ESR and CRP. Serum amyloid A protein (SAA), which is also predominantly synthesized in the liver, would be an alternative (and superior) marker for AA amyloid. However, SAA quantitation is not always available outside specialist centers. In the United States, it is available through the multi-biomarker disease activity (MBDA) test (Vectra DA) or inflammatory bowel disease diagnostic panels. Proinflammatory cytokine measurements can be obtained either individually or as part biomarker screens [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Tests for monoclonal immunoglobulins in serum, such as immunofixation and measurement of free immunoglobulin light chains, are useful in excluding AL amyloidosis but must be interpreted with caution, as incidental monoclonal gammopathies are present in 5 to 8 percent of patients over 70 years of age, and in some cases of AL amyloidosis, the clone may not be detected in the serum. (See
         <a class="medical medical_review" href="/z/d/html/6668.html" rel="external">
          "Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">
          "Laboratory methods for analyzing monoclonal proteins"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Serum amyloid P component scintigraphy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amyloid fibrils avidly bind both apolipoprotein E and serum amyloid P component (SAP). Tissue amyloid deposits may be identifiable by scintigraphy following the intravenous injection of technetium- or radioiodine-labeled SAP. The sensitivity and specificity of SAP scanning are discussed in detail elsewhere. This test is available in the United Kingdom and the Netherlands but is not available in the United States. (See
         <a class="medical medical_review" href="/z/d/html/6668.html" rel="external">
          "Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis", section on 'Serum amyloid P component scintigraphy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H678549639">
         <span class="h3">
          Other imaging modalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potential ligands for imaging of AA amyloid include antibodies with reactivity to the subunit protein, peptides that bind to tissue AA, and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) [
         <a href="#rid98">
          98-100
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the presence of biopsy-established amyloidosis, the differential diagnosis of AA amyloidosis includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunoglobulin light chain amyloidosis
         </strong>
         – Immunoglobulin light chain (AL; primary) amyloidosis is due to the tissue deposition of fragments of monoclonal immunoglobulin light chains. The plasma cell proliferation in this disorder leads to the presence of a paraprotein in the serum (as an M protein on protein immunoelectrophoresis or immunofixation or as evidenced by increased serum free light chains) or urine (as monoclonal light chains) in approximately 90 percent of cases. Although virtually all patients have multisystem amyloid deposition, it is not uncommon to present with organ-dominant disease. (See
         <a class="medical medical_review" href="/z/d/html/6668.html" rel="external">
          "Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who have a monoclonal gammopathy of undetermined significance (MGUS) may require additional diagnostic studies, as approximately 10 percent of such patients have been found to have a type of amyloidosis other than AL amyloid.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hereditary amyloidosis
         </strong>
         – Heritable amyloidoses result from mutations in gene coding for one of several different proteins. A thorough family history aids in the exclusion of these heritable disorders. AA-specific immunohistochemical staining on biopsy will confirm AA amyloidosis and thus exclude a hereditary form. (See
         <a class="local">
          ''Hereditary' AA amyloidosis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5590.html" rel="external">
          "Genetic factors in the amyloid diseases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dialysis-related amyloidosis
         </strong>
         – Dialysis-related amyloidosis is due to deposition of fibrils derived from beta-2 microglobulin, which accumulates in patients with end-stage kidney disease who are being maintained for prolonged periods of time by dialysis. This disorder has a predilection for osteoarticular structures. Although dialysis-related amyloidosis is associated with chronic hemo- or peritoneal dialysis, the amyloid rarely involves the kidney itself. Dialysis-related amyloidosis is almost exclusively a disease of patients on long-term renal replacement therapy. (See
         <a class="medical medical_review" href="/z/d/html/1983.html" rel="external">
          "Dialysis-related amyloidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age-related (senile) systemic amyloidosis
         </strong>
         – Deposition of otherwise normal (wild-type) transthyretin in myocardium and other sites is referred to as age-related (senile) systemic amyloidosis. Age-related systemic amyloidosis very rarely affects the kidney, the major target organ being the heart. Localization of amyloid deposition to the myocardium, immunohistochemistry with antibodies to transthyretin, and proteomic testing may also be used to distinguish this form of amyloid from AA. (See
         <a class="medical medical_review" href="/z/d/html/122846.html" rel="external">
          "Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Wild-type transthyretin systemic amyloidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Organ-specific localized amyloidosis
         </strong>
         – The coincidental occurrence of organ-specific amyloidosis in a patient with a systemic rheumatic or chronic inflammatory disorder could cause confusion with AA amyloidosis, but localized AA amyloid is rare. When found, localized amyloidosis is usually AL-type amyloidosis that is diagnosed on histology or mass spectrometry; it is very rarely hereditary. It has been reported in association with sarcoidosis, Sjögren's disease, and occasionally other conditions. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Organ-specific amyloid'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AA amyloidosis (previously known as secondary [AA] amyloidosis) is a disorder characterized by the extracellular tissue deposition of fibrils that are predominantly composed of fragments of serum amyloid A (SAA) protein, an acute phase reactant. AA amyloidosis may complicate a number of chronic inflammatory conditions. The incidence appears to be falling and in western nations ranges from 0.5 to 0.86 percent. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Causes and relation to rheumatic diseases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most common underlying disorders associated with AA amyloidosis in the United States and Europe include rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), inflammatory bowel disease, psoriatic arthritis, familial periodic fever syndromes, chronic infections, and certain neoplasms. Inflammation of unknown etiology appears to be responsible for an increasing proportion, perhaps reflecting more effective treatment of the inflammatory arthritides and inflammatory bowel disease with biologic agents. (See
         <a class="local">
          'Causes and relation to rheumatic diseases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In some eastern Mediterranean countries (eg, Turkey, Armenia), familial Mediterranean fever and certain
         <em>
          MEFV
         </em>
         mutations are more common causes and associations with AA amyloidosis than in North America and Europe. Chronic infections are responsible for a larger proportion of patients with AA amyloid in the developing world than in the United States and Europe. It may precede and/or complicate familial Mediterranean fever and tumor necrosis factor receptor-1 (TNFR1) associated periodic syndrome monogenic autoinflammatory diseases, as well as complicate sporadic and hereditary diseases such as Schnitzler syndrome, JIA, and adult-onset Still's disease. Susceptibility to AA amyloidosis among the various rheumatic diseases is determined by duration and severity of inflammation with contributions from additional genetic and environmental factors. (See
         <a class="local">
          'Causes and relation to rheumatic diseases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We recommend tissue biopsy in all cases of suspected AA amyloidosis to confirm the presence of amyloid. The abdominal fat is a generally safe and reasonably sensitive site for initial biopsy. If a fat aspiration biopsy is negative, then we obtain a biopsy of a clinically involved organ. Alternative sites to the abdominal fat pad for the screening biopsy include the rectum and gingiva. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Selection of biopsy site'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients in whom amyloid is present on biopsy, further immunofluorescence or immunochemical staining is indicated for identification of AA protein and, in some cases, for kappa and lambda light chains. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We perform testing of serum and urine for monoclonal immunoglobulins and of serum for free light chains to help exclude immunoglobulin light chain (AL; primary) amyloidosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Laboratory testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the presence of biopsy-established amyloidosis, the differential diagnosis of AA amyloidosis includes AL amyloidosis, hereditary amyloidosis, dialysis-related amyloidosis, age-related systemic amyloidosis, and organ-specific amyloidosis. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Papa R, Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin North Am 2018; 44:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunger AF, Nienhuis HLA, Bijzet J, Hazenberg BPC. Causes of AA amyloidosis: a systematic review. Amyloid 2020; 27:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westermark P, Nilsson GT. Demonstration of amyloid protein AA in old museum specimens. Arch Pathol Lab Med 1984; 108:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deshayes S, Aouba A, Grateau G, Georgin-Lavialle S. Infections and AA amyloidosis: An overview. Int J Clin Pract 2021; 75:e13966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nienhuis HL, Bijzet J, Hazenberg BP. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel) 2016; 2:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laiho K, Tiitinen S, Kaarela K, et al. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin Rheumatol 1999; 18:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panizo N, Rivera F, López-Gómez JM, Spanish Registry of Glomerulonephritis. Decreasing incidence of AA amyloidosis in Spain. Eur J Clin Invest 2013; 43:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane T, Pinney JH, Gilbertson JA, et al. Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. Amyloid 2017; 24:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol 1994; 8:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Real de Asúa D, Costa R, Galván JM, et al. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol 2014; 6:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girnius S, Dember L, Doros G, Skinner M. The changing face of AA amyloidosis: a single center experience. Amyloid 2011; 18 Suppl 1:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bunker D, Gorevic P. AA amyloidosis: Mount Sinai experience, 1997-2012. Mt Sinai J Med 2012; 79:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356:2361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunter J, McGregor L. Do inflammatory rheumatic diseases still cause as much harm through amyloidosis? Amyloid 2011; 18 Suppl 1:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westermark P, Westermark GT. Review. Reflections on amyloidosis in Papua New Guinea. Philos Trans R Soc Lond B Biol Sci 2008; 363:3701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ensari C, Ensari A, Tümer N, Ertug E. Clinicopathological and epidemiological analysis of amyloidosis in Turkish patients. Nephrol Dial Transplant 2005; 20:1721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cazeneuve C, Sarkisian T, Pêcheux C, et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. Am J Hum Genet 1999; 65:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atoyan S, Hayrapetyan H, Sarkisian T, Ben-Chetrit E. MEFV and SAA1 genotype associations with clinical features of familial Mediterranean fever and amyloidosis in Armenia. Clin Exp Rheumatol 2016; 34:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pras M, Franklin EC, Shibolet S, Frangione B. Amyloidosis associated with renal cell carcinoma of the AA type. Am J Med 1982; 73:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piskin O, Alacacioglu I, Ozkal S, et al. A patient with diffuse large B-cell non-Hodgkin's lymphoma and AA type amyloidosis. J BUON 2008; 13:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muzaffar J, Katragadda L, Haider S, et al. Waldenström's macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant. Acta Haematol 2013; 130:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terré A, Colombat M, Cez A, et al. AA amyloidosis complicating monoclonal gammopathies, an unusual feature validating the concept of "monoclonal gammopathy of inflammatory significance"? Int J Clin Pract 2021; 75:e14817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimojima Y, Takei Y, Tazawa K, et al. Histopathological regression of systemic AA amyloidosis after surgical treatment of a localized Castleman's disease. Amyloid 2006; 13:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogita M, Hoshino J, Sogawa Y, et al. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol 2007; 68:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fayand A, Boutboul D, Galicier L, et al. Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review. Amyloid 2019; 26:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skinner M, Pinnette A, Travis WD, et al. Isolation and sequence analysis of amyloid protein AA from a patient with cystic fibrosis. J Lab Clin Med 1988; 112:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stankovic Stojanovic K, Hubert D, Leroy S, et al. Cystic fibrosis and AA amyloidosis: a survey in the French cystic fibrosis network. Amyloid 2014; 21:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lejmi H, Jen KY, Olson JL, et al. Characteristics of AA amyloidosis patients in San Francisco. Nephrology (Carlton) 2016; 21:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girouard SD, Falk RH, Rennke HG, Merola JF. Hidradenitis suppurativa resulting in systemic amyloid A amyloidosis: a case report and review of the literature. Dermatol Online J 2012; 18:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schandorff KD, Miller IM, Krustrup D, et al. Renal amyloid A amyloidosis as a complication of hidradenitis suppurativa. Clin Nephrol 2016; 86:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stankovic Stojanovic K, Georgin-Lavialle S, Poitou C, et al. AA amyloidosis is an emerging cause of nephropathy in obese patients. Eur J Intern Med 2017; 39:e18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blank N, Hegenbart U, Dietrich S, et al. Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. Amyloid 2018; 25:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith ME, Ansell BM, Bywaters EG. Mortality and prognosis related to the amyloidosis of Still's disease. Ann Rheum Dis 1968; 27:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roztropowicz-Denisiewicz K, Madyk E, Romicka A, Szymanska-Jagiello W. Variability of the course of amyloidosis in children with rheumatoid arthritis. Ped Pol 1974; 49:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filipowicz-Sosnowska AM, Roztropowicz-Denisiewicz K, Rosenthal CJ, Baum J. The amyloidosis of juvenile rheumatoid arthritis--comparative studies in Polish and American children. I. Levels of serum SAA protein. Arthritis Rheum 1978; 21:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007; 56:1706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Husby G. Amyloidosis and rheumatoid arthritis. Clin Exp Rheumatol 1985; 3:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Päi S, Helin H, Isomäki H. Frequency of amyloidosis in Estonian patients with rheumatoid arthritis. Scand J Rheumatol 1993; 22:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gómez-Casanovas E, Sanmartí R, Solé M, et al. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 2001; 44:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okuda Y, Takasugi K, Oyama T, et al. [Amyloidosis in rheumatoid arthritis--clinical study of 124 histologically proven cases]. Ryumachi 1994; 34:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakhlu A, Krisnani N, Hissaria P, et al. Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis. J Rheumatol 2003; 30:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Mansoury TM, Hazenberg BP, El Badawy SA, et al. Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. Ann Rheum Dis 2002; 61:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiland P, Wojtala R, Goodacre J, Szechinski J. The prevalence of subclinical amyloidosis in Polish patients with rheumatoid arthritis. Clin Rheumatol 2004; 23:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Hakala M. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology (Oxford) 1999; 38:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sellars L, Siamopoulos K, Wilkinson R, et al. Renal biopsy appearances in rheumatoid disease. Clin Nephrol 1983; 20:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourke BE, Woodrow DF, Scott JT. Proteinuria in rheumatoid arthritis--drug-induced or amyloid? Ann Rheum Dis 1981; 40:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ludwin D, Alexopoulou I, Esdaile JM, Tugwell P. Renal biopsy specimens from patients with rheumatoid arthritis and apparently normal renal function after therapy with cyclosporine. Canadian Multicentre Rheumatology Group. Am J Kidney Dis 1994; 23:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazenberg BP, van Rijswijk MH. Where has secondary amyloid gone? Ann Rheum Dis 2000; 59:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuroda T, Tanabe N, Harada T, et al. Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 2006; 25:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uda H, Yokota A, Kobayashi K, et al. Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol 2006; 33:1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koivuniemi R, Paimela L, Suomalainen R, Leirisalo-Repo M. Amyloidosis as a cause of death in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koivuniemi R, Paimela L, Suomalainen R, et al. Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 2008; 15:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo P. Amyloidosis in children. Baillieres Clin Rheumatol 1994; 8:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Immonen K, Savolainen A, Kautiainen H, Hakala M. Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis. J Rheumatol 2008; 35:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pamuk ÖN, Kalyoncu U, Aksu K, et al. A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients. Rheumatol Int 2016; 36:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CRUICKSHANK B. Pathology of ankylosing spondylitis. Bull Rheum Dis 1960; 10:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gratacos J, Orellana C, Sanmarti R, et al. Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration. J Rheumatol 1997; 24:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovacsovics-Bankowski M, Zufferey P, So AK, Gerster JC. Secondary amyloidosis: a severe complication of ankylosing spondylitis. Two case-reports. Joint Bone Spine 2000; 67:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh G, Kumari N, Aggarwal A, et al. Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 2007; 34:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aktas Yilmaz B, Düzgün N, Mete T, et al. AA amyloidosis associated with systemic lupus erythematosus: impact on clinical course and outcome. Rheumatol Int 2008; 28:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pepys MB. Serum C-reactive protein, serum amyloid P-component and serum amyloid A protein in autoimmune disease. Clin Immunol Allergy 1981; 1:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Migita K, Eguchi K, Tsukada T, et al. Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Lab Invest 1996; 75:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson CJ, Gregory MC, Groggel GC, Clegg DO. Amyloidosis and Reiter's syndrome: report of a case and review of the literature. Am J Kidney Dis 1989; 14:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mpofu S, Teh LS, Smith PJ, et al. Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology (Oxford) 2003; 42:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosemehmetoglu K, Baydar DE. Renal amyloidosis in Behçet's disease: clinicopathologic features of 8 cases. Int Urol Nephrol 2013; 45:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wada Y, Nishida H, Kohno K, et al. AA amyloidosis in Takayasu's arteritis--long-term survival on maintenance haemodialysis. Nephrol Dial Transplant 1999; 14:2478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura S, Morishita M, Yang CL, et al. An elderly female who survived more than 30 years following a diagnosis of Takayasu's arteritis, complicated by fatal intestinal amyloidosis. Clin Rheumatol 2006; 25:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruz I, Oliveira AP, Lopes JM, et al. Whipple's disease and renal amyloidosis. Am J Gastroenterol 1993; 88:1954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escribá A, Morales E, Albizúa E, et al. Secondary (AA-type) amyloidosis in patients with polymyalgia rheumatica. Am J Kidney Dis 2000; 35:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moraga, Sicilia JJ, Blanco J, Ubeda I. Giant cell arteritis and renal amyloidosis: report of a case. Clin Nephrol 2001; 56:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hočevar A, Lestan B, Šemrl SS, et al. AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab. Amyloid 2013; 20:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ter Borg EJ, Wegewijs MA, de Bruin P. Gout and AA Amyloidosis: A Case Report and Review of the Literature. J Clin Rheumatol 2017; 23:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong BC, Wong KL, Ip MS, et al. Sjögren's syndrome with amyloid A presenting as multiple pulmonary nodules. J Rheumatol 1994; 21:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karim F, Clahsen-van Groningen M, van Laar JA. AA Amyloidosis and IgG4-Related Disease. N Engl J Med 2017; 376:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saatçi U, Ozen S, Ozdemir S, et al. Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr 1997; 156:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sikora J, Kmochová T, Mušálková D, et al. A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. Kidney Int 2022; 101:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soriano A, Manna R. Familial Mediterranean fever: new phenotypes. Autoimmun Rev 2012; 12:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delaleu J, Deshayes S, Rodrigues F, et al. Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis: a national case series and systematic review. Rheumatology (Oxford) 2021; 60:5775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palladini G, Merlini G. The elusive pathogenesis of Schnitzler syndrome. Blood 2018; 131:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha A, Chopra Y, Theis JD, et al. AA amyloidosis associated with systemic-onset juvenile idiopathic arthritis. Am J Kidney Dis 2013; 62:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delplanque M, Pouchot J, Ducharme-Bénard S, et al. AA amyloidosis secondary to adult onset Still's disease: About 19 cases. Semin Arthritis Rheum 2020; 50:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Euvrard R, Fournier T, Georgescu D, et al. VEXAS syndrome-related AA amyloidosis: a case report. Rheumatology (Oxford) 2021; 61:e15.
          </a>
         </li>
         <li class="breakAll">
          Kluve-Beckerman B, Benson MD. AA amyloidosis in patients with no known inflammatory condition. Abstract PB15. XIII Intl Symposium on Amyloidosis, May 6-10, 2012.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palladini G, Riva E, Basset M, et al. Prognostication of survival and progression to dialysis in AA amyloidosis. Amyloid 2017; 24:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 1991; 70:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westermark GT, Sletten K, Westermark P. Massive vascular AA-amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand J Immunol 1989; 30:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hiki Y, Horii A, Kokubo T, et al. A case of rheumatoid arthritis with renal tubular amyloidosis. Nephron 1994; 68:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westermark GT, Sletten K, Grubb A, Westermark P. AA-amyloidosis. Tissue component-specific association of various protein AA subspecies and evidence of a fourth SAA gene product. Am J Pathol 1990; 137:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hachulla E, Grateau G. Diagnostic tools for amyloidosis. Joint Bone Spine 2002; 69:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang GC, Gallo GR. Protein A-gold immunoelectron microscopic study of amyloid fibrils, granular deposits, and fibrillar luminal aggregates in renal amyloidosis. Am J Pathol 1990; 137:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Picken MM, Pelton K, Frangione B, Gallo G. Primary amyloidosis A. Immunohistochemical and biochemical characterization. Am J Pathol 1987; 129:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy CL, Wang S, Williams T, et al. Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol 2006; 412:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazenberg BP, Bijzet J, Limburg PC, et al. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid 2007; 14:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavatelli F, Perlman DH, Spencer B, et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 2008; 7:1570.
          </a>
         </li>
         <li class="breakAll">
          Dogan A. Classification of amyloidosis by mass spectometry-based proteomics. In: Amyloid &amp; Related Disorders: Surgical Pathology &amp; Clinical Correlations, Pickens MM, et al (Eds), Springer, 2012. p.261.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brambilla F, Lavatelli F, Di Silvestre D, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012; 119:1844.
          </a>
         </li>
         <li class="breakAll">
          Marshall J, McNally W, Muller D, et al. In vivo radioimmunodetection of amyloid deposits in experimental amyloidosis. In: Amyloidosis, Glenner GG, Osserman EF, Benditt EP, et al (Eds), Plenum Press, 1986. p.163.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin EB, Williams A, Richey T, et al. Comparative evaluation of p5+14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis. Sci Rep 2016; 6:22695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Zhao B, Song T, Sun J. Lung cancer combined with diffuse peritoneal and mesenteric amyloidosis detected on 18F-FDG PET/CT: A case report. Medicine (Baltimore) 2021; 100:e25961.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5602 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30274625" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Secondary, AA, Amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31766892" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Causes of AA amyloidosis: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6198999" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Demonstration of amyloid protein AA in old museum specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33368925" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Infections and AA amyloidosis: An overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27536687" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The Prevalence and Management of Systemic Amyloidosis in Western Countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10357116" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23683125" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Decreasing incidence of AA amyloidosis in Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28686088" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7954866" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The epidemiology of AL and AA amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25378951" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Systemic AA amyloidosis: epidemiology, diagnosis, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21838497" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The changing face of AA amyloidosis: a single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23239212" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : AA amyloidosis: Mount Sinai experience, 1997-2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11454373" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17554117" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Natural history and outcome in systemic AA amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21838490" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Do inflammatory rheumatic diseases still cause as much harm through amyloidosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18849285" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Review. Reflections on amyloidosis in Papua New Guinea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15972323" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Clinicopathological and epidemiological analysis of amyloidosis in Turkish patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10364520" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27791951" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : MEFV and SAA1 genotype associations with clinical features of familial Mediterranean fever and amyloidosis in Armenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7124769" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Amyloidosis associated with renal cell carcinoma of the AA type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18404797" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A patient with diffuse large B-cell non-Hodgkin's lymphoma and AA type amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23689541" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Waldenström's macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34490695" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : AA amyloidosis complicating monoclonal gammopathies, an unusual feature validating the concept of "monoclonal gammopathy of inflammatory significance"?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17062386" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Histopathological regression of systemic AA amyloidosis after surgical treatment of a localized Castleman's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17915620" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31364863" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3171350" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Isolation and sequence analysis of amyloid protein AA from a patient with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25054230" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Cystic fibrosis and AA amyloidosis: a survey in the French cystic fibrosis network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26370715" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Characteristics of AA amyloidosis patients in San Francisco.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22301039" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Hidradenitis suppurativa resulting in systemic amyloid A amyloidosis: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27340120" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Renal amyloid A amyloidosis as a complication of hidradenitis suppurativa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28214252" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : AA amyloidosis is an emerging cause of nephropathy in obese patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29364741" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Obesity is a significant susceptibility factor for idiopathic AA amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5646432" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Mortality and prognosis related to the amyloidosis of Still's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Variability of the course of amyloidosis in children with rheumatoid arthritis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/737000" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The amyloidosis of juvenile rheumatoid arthritis--comparative studies in Polish and American children. I. Levels of serum SAA protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17469185" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3893817" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Amyloidosis and rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8235496" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Frequency of amyloidosis in Estonian patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11212178" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7863383" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : [Amyloidosis in rheumatoid arthritis--clinical study of 124 histologically proven cases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12734887" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11779757" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15168143" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The prevalence of subclinical amyloidosis in Polish patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10402068" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6627762" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Renal biopsy appearances in rheumatoid disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6787994" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Proteinuria in rheumatoid arthritis--drug-induced or amyloid?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8311085" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Renal biopsy specimens from patients with rheumatoid arthritis and apparently normal renal function after therapy with cyclosporine. Canadian Multicentre Rheumatology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10913049" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Where has secondary amyloid gone?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16267602" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16881107" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18578961" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Amyloidosis as a cause of death in patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19065298" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Amyloidosis is frequently undetected in patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7954869" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Amyloidosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18381779" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27221456" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13813081" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Pathology of ankylosing spondylitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9150081" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10769106" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Secondary amyloidosis: a severe complication of ankylosing spondylitis. Two case-reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17295439" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Prevalence of subclinical amyloidosis in ankylosing spondylitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17687556" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : AA amyloidosis associated with systemic lupus erythematosus: impact on clinical course and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Serum C-reactive protein, serum amyloid P-component and serum amyloid A protein in autoimmune disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8804360" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2679059" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Amyloidosis and Reiter's syndrome: report of a case and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12595637" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22961375" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Renal amyloidosis in Behçet's disease: clinicopathologic features of 8 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10528678" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : AA amyloidosis in Takayasu's arteritis--long-term survival on maintenance haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16292468" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : An elderly female who survived more than 30 years following a diagnosis of Takayasu's arteritis, complicated by fatal intestinal amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7694455" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Whipple's disease and renal amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10620555" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Secondary (AA-type) amyloidosis in patients with polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11758014" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Giant cell arteritis and renal amyloidosis: report of a case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24106820" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28538281" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Gout and AA Amyloidosis: A Case Report and Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8151574" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Sjögren's syndrome with amyloid A presenting as multiple pulmonary nodules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28177871" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : AA Amyloidosis and IgG4-Related Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9266193" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34560138" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22878273" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Familial Mediterranean fever: new phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33715002" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis: a national case series and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29496698" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The elusive pathogenesis of Schnitzler syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23664546" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : AA amyloidosis associated with systemic-onset juvenile idiopathic arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31488308" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : AA amyloidosis secondary to adult onset Still's disease: About 19 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34498034" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : VEXAS syndrome-related AA amyloidosis: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34498034" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : VEXAS syndrome-related AA amyloidosis: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28434292" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Prognostication of survival and progression to dialysis in AA amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2067409" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Secondary systemic amyloidosis: response and survival in 64 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2587936" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Massive vascular AA-amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7838272" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : A case of rheumatoid arthritis with renal tubular amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2386201" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : AA-amyloidosis. Tissue component-specific association of various protein AA subspecies and evidence of a fourth SAA gene product.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12537260" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Diagnostic tools for amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2240166" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Protein A-gold immunoelectron microscopic study of amyloid fibrils, granular deposits, and fibrillar luminal aggregates in renal amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3425691" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Primary amyloidosis A. Immunohistochemical and biochemical characterization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17046651" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Characterization of systemic amyloid deposits by mass spectrometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17577686" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18474516" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18474516" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21917755" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21917755" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26936002" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Comparative evaluation of p5+14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34032706" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Lung cancer combined with diffuse peritoneal and mesenteric amyloidosis detected on 18F-FDG PET/CT: A case report.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
